



## Astria Therapeutics to Present at Upcoming Jefferies Healthcare Conference

May 30, 2024

BOSTON--(BUSINESS WIRE)--May 30, 2024-- [Astria Therapeutics, Inc.](#) (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will participate in a fireside chat at the upcoming Jefferies Healthcare Conference on Thursday, June 6<sup>th</sup> at 10:00am ET in New York, NY.

A webcast of the presentation can be accessed at the following link: <https://wsw.com/webcast/jeff302/atxs/1868288>. An archived replay of the presentation will be available in the investors section of [www.astriatx.com](http://www.astriatx.com) for 30 days following the event.

### **About Astria Therapeutics:**

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Our second program, STAR-0310, is a monoclonal antibody OX40 antagonist in preclinical development for the treatment of atopic dermatitis. Learn more about our company on our website, [www.astriatx.com](http://www.astriatx.com), or follow us on X and Instagram @AstriaTx and on Facebook and LinkedIn.

View source version on [businesswire.com](http://businesswire.com): <https://www.businesswire.com/news/home/20240530854297/en/>

Astria:

### **Investor Relations and Media:**

Elizabeth Higgins

[investors@astriatx.com](mailto:investors@astriatx.com)

Source: Astria Therapeutics, Inc.